Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 02 Dec 2025
Merck granted fast track designation by the US FDA for MK-2214 for the treatment of Alzheimer's disease
1 December 2025 - MK-2214, an investigational novel antibody targeting phosphorylated serine 413 (pS413) tau. ...
Posted by Michael Wonder on 02 Dec 2025
New Zealand Pharmaceutical Schedule - 1 December 2025
1 December 2025 - The December 2025 issue of the New Zealand Pharmaceutical Schedule is now available and in effect. ...
Posted by Michael Wonder on 02 Dec 2025
Ionis receives US FDA breakthrough therapy designation for olezarsen for severe hypertriglyceridaemia
1 December 2025 - On track to submit supplemental new drug application by end of year. ...
Posted by Michael Wonder on 01 Dec 2025
Sound Pharmaceuticals receives FDA breakthrough therapy designation for SPI-1005 to treat Meniere’s disease
1 December 2025 - Sound Pharmaceuticals is pleased to announce that the FDA has granted its investigational new drug, SPI-1005, breakthrough ...
Posted by Michael Wonder on 01 Dec 2025
Cullinan Therapeutics receives FDA fast track designation for CLN-049, a novel FLT3xCD3 T cell engager, in relapsed/refractory acute myeloid leukemia
1 December 2025 - Cullinan Therapeutics today announced that the US FDA has granted fast track designation to CLN-049 for ...
Posted by Michael Wonder on 01 Dec 2025
Vanda Pharmaceuticals provides regulatory update on tradipitant for motion sickness
28 November 2025 - Vanda Pharmaceuticals today announced updates regarding tradipitant for motion sickness. ...
Posted by Michael Wonder on 01 Dec 2025
Lilly lowers the price of Zepbound (tirzepatide) single-dose vials
1 December 2025 - Eli Lilly announced Zepbound (tirzepatide) single dose vials will now be available at lower prices on LillyDirect, ...
Posted by Michael Wonder on 01 Dec 2025
Changes to NICE’s cost effectiveness thresholds confirmed
1 December 2025 - The Government has today announced that it will increase the thresholds NICE uses in evaluations of new ...
Posted by Michael Wonder on 30 Nov 2025
Schedule of Pharmaceutical Benefits - 1 December 2025
1 December 2025 - The December 2025 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. ...
Posted by Michael Wonder on 30 Nov 2025
Korea launches sweeping drug pricing reform to curb generic dominance
29 November 2025 - The Government will launch a large scale overhaul of the drug pricing system starting in the ...
Posted by Michael Wonder on 29 Nov 2025
CMS Delivers Savings for Seniors on 15 Major Drugs for Cancer and Chronic Disease
25 November 2025 - CMS today announced a net savings of 44%, or $12 billion, from last year’s negotiated Medicare ...
Posted by Michael Wonder on 29 Nov 2025
Government considers new PBS fund to slash wait times for treatments
29 November 2025 - The Albanese Government could introduce a new health fund by the next federal budget to bankroll ...
Posted by Michael Wonder on 28 Nov 2025
Utilisation of real world evidence in regulatory approvals for multiple myeloma therapies
27 November 2025 - Multiple myeloma is a rare, incurable haematologic malignancy that demands ongoing innovation in treatment approaches given frequent ...
Posted by Michael Wonder on 28 Nov 2025
Easier access to HIV medicines from next year
27 November 2025 - PHARMAC is making a change to ensure everyone who needs HIV medicines can access them more ...
Posted by Michael Wonder on 28 Nov 2025
PHARMAC proposes funding for rare disorder treatment
26 November 2025 - PHARMAC is proposing to fund nitisinone for people with the rare disorders - tyrosinaemia type 1 ...